Amicus (FOLD) Price & Analysis

Compare

1,082 Followers

FOLD Stock Chart & Stats

$8.87

-$0.18(-1.98%)

At close: Jan 08 4:00 PM EST

$8.87

-$0.18(-1.98%)

Day’s Range― - ―

52-Week Range$5.51 - $11.36

Previous CloseN/A

Volume320.41K

Average Volume (3M)5.46M

Market Cap

$2.84B

Enterprise Value$2.63B

Total Cash (Recent Filing)$263.84M

Total Debt (Recent Filing)$442.82M

Price to Earnings (P/E)―

Beta0.58

Next Earnings

Feb 19, 2026

EPS Estimate

0.07

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.06

Shares Outstanding308,533,540

10 Day Avg. Volume5,490,185

30 Day Avg. Volume5,458,250

Financial Highlights & Ratios

PEG Ratio0.79

Price to Book (P/B)14.78

Price to Sales (P/S)5.43

P/FCF Ratio-76.57

Enterprise Value/Market Cap0.93

Enterprise Value/Revenue4.38

Enterprise Value/Gross Profit4.90

Enterprise Value/Ebitda44.29

Forecast

1Y Price Target

$15.88

Price Target Upside79.03% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Intellectual PropertyThe US District Court for the District of Delaware has denied Aurobindo’s motion for summary judgement of patent ineligibility, supporting franchise durability.

Pipeline ExpansionFOLD announced new future US PomOp manufacturing and in-licensed Ph3 DMX-200 in FSGS, indicating pipeline expansion.

Revenue GrowthAmicus reported strong revenue growth and continued momentum in its core Pompe and Fabry disease franchises, positioning the company for GAAP profitability for 2H25 and projecting over $1B in total revenue by fiscal year 2028.

Bears Say

Increased ExpensesFY25 non-GAAP operating expenses guidance increased due to a $30M upfront licensing payment.

Patent ChallengesThe judge flagged an older patent and a key precedent as issues to address, which indicates potential challenges ahead.

Revenue Miss1Q25 PomOp and Galafold revenues both missed consensus estimates due to higher UK VPAG rebates.

Amicus News

Amicus price target raised to $19 from $18 at JPMorgan

JPMorgan raised the firm’s price target on Amicus (FOLD) to $19 from $18 and keeps an Overweight rating...

2d ago

FOLD

Amicus price target raised to $11 from $9 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Amicus (FOLD) to $11 from $9 and keeps a Neutral...

3d ago

FOLD

Amicus reports Q3 non-GAAP EPS 17c, consensus 12c

Reports Q3 revenue $169M, consensus $165.71M. “Amicus (FOLD) achieved yet another impressive quarter, delivering revenue growth of 17...

4d ago

FOLD

Amicus anticipates surpassing $1B in sales in 2028

Amicus (FOLD) is focused on delivering significant long-term revenue growth and anticipates surpassing $1 billion in total sales...

4d ago

FOLD

Amicus sees FY25 total revenue growth 15%-22%

Sees Galafold Revenue Growth 10% to 15%; Pombiliti + Opfolda Revenue Growth 50% to 65%; Gross Margin Mid...

4d ago

FOLD

Amicus Therapeutics Reports Strong Q3 2025 Results

Amicus Therapeutics ( ($FOLD) ) has released its Q3 earnings. Here is a breakdown of the information Amicus...

4d ago

FOLD

Amicus Therapeutics Reports Strong Q3 Earnings Growth

Amicus Therapeutics (($FOLD)) has held its Q3 earnings call. Read on for the main highlights of the call....

4d ago

FOLD

Amicus’s Strong Financial Performance and Growth Prospects Earns Buy Rating from Analyst

Analyst Ritu Baral of TD Cowen maintained a Buy rating on Amicus, with a price target of $20.00....

4d ago

FOLD

Amicus Therapeutics: Strong Q3 Performance and Strategic Advancements Justify Buy Rating

Amicus, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Gil Blum from Needham...

4d ago

FOLD

FOLD Upcoming Earnings Report: What to Expect?

Amicus Therapeutics (FOLD) is scheduled to report 3rd quarter earnings on 11/04/2025, before the market opens. Regarding Q3...

7d ago

FOLD

Target initiated, Nike upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

2M ago

Needham upgrades Amicus to Buy on reduced regulatory risk

Needham upgraded Amicus (FOLD) to Buy from Hold with a $14 price target The FDA’s decision to no...

2M ago

FOLD

Amicus Stock Upgraded to Buy: DMX-200’s Potential and Galafold’s Growth Drive Investment Opportunity

Needham analyst Gil Blum upgraded the rating on Amicus to a Buy today, setting a price target of...

2M ago

FOLD

Amicus upgraded to Buy from Hold at Needham

Needham upgraded Amicus (FOLD) to Buy from Hold with a $14 price target Published first on TheFly –...

2M ago

FOLD

FOLD FAQ

What was Amicus Therapeutics’s price range in the past 12 months?

Amicus Therapeutics lowest stock price was $5.51 and its highest was $11.36 in the past 12 months.

What is Amicus Therapeutics’s market cap?

Amicus Therapeutics’s market cap is $2.84B.

When is Amicus Therapeutics’s upcoming earnings report date?

Amicus Therapeutics’s upcoming earnings report date is Feb 19, 2026 which is in 102 days.

How were Amicus Therapeutics’s earnings last quarter?

Amicus Therapeutics released its earnings results on Nov 04, 2025. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.039 by $0.021.

Is Amicus Therapeutics overvalued?

According to Wall Street analysts Amicus Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Amicus Therapeutics pay dividends?

Amicus Therapeutics does not currently pay dividends.

What is Amicus Therapeutics’s EPS estimate?

Amicus Therapeutics’s EPS estimate is 0.07.

How many shares outstanding does Amicus Therapeutics have?

Amicus Therapeutics has 308,533,540 shares outstanding.

What happened to Amicus Therapeutics’s price movement after its last earnings report?

Amicus Therapeutics reported an EPS of $0.06 in its last earnings report, beating expectations of $0.039. Following the earnings report the stock price went up 1.467%.

Which hedge fund is a major shareholder of Amicus Therapeutics?

Currently, no hedge funds are holding shares in FOLD

Amicus Stock Smart Score

Neutral

Fundamentals

Return on Equity

-6.87%

Trailing 12-Months

Asset Growth

10.46%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Amicus Therapeutics

Amicus Therapeutics, Inc. (FOLD) is a biopharmaceutical company focused on developing innovative therapies for rare and devastating diseases, particularly those caused by genetic mutations. The company operates primarily in the biotechnology sector, concentrating on the development of treatments for lysosomal storage disorders, including Fabry disease and Pompe disease. Amicus is known for its proprietary enzyme replacement therapies and small molecule pharmacological chaperones, which are designed to improve patient outcomes and quality of life.

Amicus (FOLD) Earnings & Revenues

Historic Earnings Reports

FOLD Company Deck

FOLD Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call for Amicus Therapeutics highlights strong financial performance with notable revenue growth and GAAP profitability, driven by their flagship products and global market expansion. Despite some increase in costs and early-stage profitability, the company's strategic focus on expanding their product pipeline and market presence suggests a positive outlook.View all FOLD earnings summaries

FOLD Stock 12 Month Forecast

Average Price Target

$15.88

▲(79.03% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","13":"$13","22":"$22","8.5":"$8.5","17.5":"$17.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$21.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.88,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,8.5,13,17.5,22],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.03,9.95076923076923,10.87153846153846,11.792307692307691,12.713076923076922,13.633846153846154,14.554615384615385,15.475384615384614,16.396153846153844,17.316923076923075,18.237692307692306,19.158461538461538,20.07923076923077,{"y":21,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.03,9.556923076923077,10.083846153846153,10.61076923076923,11.137692307692308,11.664615384615384,12.191538461538462,12.71846153846154,13.245384615384616,13.772307692307692,14.29923076923077,14.826153846153847,15.353076923076923,{"y":15.88,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.03,9.18153846153846,9.333076923076922,9.484615384615385,9.636153846153846,9.787692307692307,9.939230769230768,10.090769230769231,10.242307692307692,10.393846153846154,10.545384615384615,10.696923076923078,10.848461538461539,{"y":11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.47,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.96,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.42,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.58,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.49,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.95,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.68,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.16,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.32,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.88,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.71,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.03,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >